Extracellular nucleotides mediate multiple physiological effects such as proliferation, differentiation, or induction of apoptosis through G protein-coupled P2Y receptors or P2X ion channels. Evaluation of the complete physiological role of nucleotides has long been hampered by a lack of potent and selective ligands for all P2 subtypes. Meanwhile, for most of the P2 receptors, selective ligands are available, but only a few potent and selective P2Y 2 receptor antagonists are described. This limits the understanding of the role of P2Y 2 receptors. The purpose of this study was to search for P2Y 2 receptor antagonists by a combinatorial screening of a library of around 415 suramin-derived compounds. Calcium fluorescence measurements at P2Y 2 receptors recombinantly expressed in human 1321N1 astrocytoma cells identified NF272 [8-(4-methyl-3-(3-phenoxycarbonylimino-benzamido)benzamido)-naphthalene-1,3,5-trisulfonic acid trisodium salt] as a competitive P2Y 2 receptor antagonist with a K i of 19 μM which is 14-fold more potent than suramin at this receptor subtype. The SCHILD analysis of competitive inhibition resulted in a pA 2 value of 5.03 ± 0.22 (mean ± SEM) with a slope not significantly different from unity. Among uracil-nucleotide-preferring P2Y receptors, NF272 shows a moderate selectivity over P2Y 4 (3.6-fold) and P2Y 6 (5.7-fold). However, NF272 is equipotent at P2Y 1 , and even more potent at P2Y 11 and P2Y 12 receptors. Up to 250 μM, NF272 showed no cytotoxicity in MTT cell viability assays in 1321N1, HEK293, and OVCAR-3 cells. Further, NF272 was able to inhibit the ATP-induced calcium signal in OVCAR-3 cells demonstrated to express P2Y 2 receptors. In conclusion, NF272 is a competitive but non-selective P2Y 2 receptor antagonist with 14-fold higher potency than suramin lacking cytotoxic effects. Therefore, NF272 may serve as a lead structure for further development of P2Y 2 receptor antagonists.
Introduction
Nucleotides such as ATP (adensosine-5′-triphosphate) and UTP (uridine-5′-triphosphate) and their corresponding diphosphates ADP (adensosine-5′-diphosphate) and UDP (uridine-5′-diphosphate) are involved in cell signaling [1, 2] . They can be released into the extracellular space after apoptosis or necrosis [3, 4] and in response to various types of stress like hypoxia or pathogen invasion [1, 2] , by exocytosis of secretory granules, through vesicular transport or through membrane channels (ABC transporters, pannexins, or connexins) [2, 5] . Upon release, nucleotides are able to interact with two distinct types of receptor families: ionotropic P2X receptors and metabotropic G protein-coupled P2Y receptors [1, 2] . The P2X receptors are trimeric ligand-gated ion channels with seven different subtypes numbered from P2X 1 Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11302-019-09663-4) contains supplementary material, which is available to authorized users. to P2X 7 . Both occurrences of heterotrimers and homotrimers are observed, distributed throughout the nervous system, vascular system, the pulmonary and digestive systems, skeletal muscle, bone, and hematopoietic cells [6, 7] . The P2Y family consists of eight receptor subtypes (P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , P2Y 11 , P2Y 12 , P2Y 13 , and P2Y 14 ) and can be subdivided based on their coupling to specific G proteins. P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , and P2Y 11 receptors couple to G q activating phospholipase C and eventually increasing intracellular calcium concentration. P2Y 12 , P2Y 13 , and P2Y 14 receptors couple to G i inhibiting adenylyl cyclase [1] . P2Y receptors are widely expressed all over the human body, e.g., in epithelial and endothelial cells, immune cells, platelets, and therefore involved in diverse (patho)physiological functions [2, 7, 8] . However, for a long time, evaluation of their complete physiological role has been hampered due to the lack of selective and potent ligands [1, 7, [9] [10] [11] [12] . Now, selective agonists and antagonists for many but not all of the P2Y receptors are available. P2Y 12 antagonists have long entered clinical use [10, 13] . Likewise for P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , P2Y 11 , and P2Y 14 receptors, selective agonists are reported as well as selective antagonists for P2Y 1 , P2Y 11 , and P2Y 12 subtypes [11] [12] [13] . P2Y 2 receptors are sensitive for ATP and UTP [1, 2] and investigated as therapeutic targets in atherosclerosis [14] [15] [16] , (lung) inflammation [3, [17] [18] [19] , cystic fibrosis [20, 21] , dry eye disease [22, 23] , hypertension [24] , pain [25, 26] , cancer [27] [28] [29] [30] [31] , or in neurodegenerative disorders [32] . In addition to the many known (patho)physiological functions, a cardiometabolic role of P2Y 2 receptors was recently described by Ali et al. [33, 34] . The dinucleoside tetraphosphates denufosol and diquafosol are clinically tested P2Y 2 receptor agonists [1, 7, 11] . Denufosol was investigated for treating patients with cystic fibrosis [20, 21] . However, clinical trials were stopped since no significant effects were observed in phase 3 [35] . In Japan and South Korea, diquafosol is now available for the treatment of dry eye disease [22, 23] . In contrast, only a few P2Y 2 receptor antagonists are described [1, [11] [12] [13] . Figure 1 a Fig. 1a) is described as a moderate and weak P2Y 2 receptor antagonist [37] . Suramin derivatives have been a rich source of lead compounds of potent and selective purinergic ligands [42] [43] [44] [45] [46] . In the present study, a suraminderived compound library containing approximately 415 compounds was screened for P2Y 2 antagonism by fluorometric calcium measurement in human recombinant P2Y 2 receptor-expressing astrocytoma cells [47] . The library consisted of large ("suramin-type") and small ("NF340-type") symmetric ureas with variations of the cap region (aryl-sulfonic acid residues), variations of the aromatic substitution pattern (e.g., methyl, ethyl, isopropyl, phenyl, methoxymethyl, tert-butyl, fluorine, or chlorine substitution), symmetrical and asymmetrical ureas, and nitro and amino precursors of the ureas (Fig. 1b) . Eventually, three compounds w e r e i d e n t i f i e d a s P 2 Y 2 a n t a g o n i s t s : N F 1 9 8 (8,8′-(carbonylbis(imino-3,1-phenylenecarbonylimino-3,1-(4-phenylphenylene) arbonylimino))bis(naphthalene-1,3,5-trisulfonic acid) hexasodium salt), NF272 (8-(4-methyl-3-(3-phenoxycarbonylimino-benzamido) benzamido)-naphthalene-1,3,5-trisulfonic acid trisodium salt), and NF292 3,3′-(Terephthaloyl-bis(imino-4,1-phenylenecarbonylimino)) bis (naphthalene-1,5-disulfonic acid) tetrasodium salt) (Fig. 1c) . Due to its low cytotoxicity, NF272 was further investigated for potency, selectivity, and competitive antagonism.
Materials and methods

Materials
All nucleotides (ATP, UTP, ADP, and ADP), cisplatin, and other reagents were obtained from Sigma-Aldrich (Taufkirchen, Germany), unless otherwise stated. Suramin (Germanin®Bayer 205) was kindly provided by Bayer AG (Leverkusen, Germany). The suramin-derived library contained approximately 415 compounds synthesized inhouse according to procedures formerly described [42, 43] . The general chemical structure is given in Fig. 1b 4 (GenBank accession no. NM_002565), P2Y 6 (GenBank accession no. N M _ 1 7 6 7 9 8 ) , P 2 Y 1 1 ( G e n B a n k a c c e s s i o n n o . NM_002566), or P2Y 1 2 (GenBank accession no. NM_176876) respectively, by using the Invitrogen FlpIn™-System® for generating stable mammalian expression cell lines according to the manufacturer's instructions. All cDNA-containing plasmids were purchased from the Missouri S&T cDNA Resource Center (Missouri, USA, www.cdna.org). Cloned cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM, PAN Biotech GmbH, Aidenbach, Germany) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin G, 100 μg/ml streptomycin (PAN Biotech GmbH, Aidenbach, Germany), and 200 μg/ml Hygromycin B (Carl Roth GmbH & Co. KG, Karlsruhe, Germany). HEK293 (Deutsche S a m m l u n g v o n M i k r o o r g a n i s m e n u n d Z e l l e n , Braunschweig, Germany) cells were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin G, and 100 μg/ml streptomycin, and OVCAR-3 (ATCC/LGC Standards GmbH, Wesel, Germany) cells were cultured in Roswell Park Memorial Institute medium (RPMI, PAN Biotech GmbH, Aidenbach, Germany) supplemented with 10% FBS, 100 U/ml penicillin G, and 100 μg/ml streptomycin. All cell lines were incubated in a humidified atmosphere at 37°C and 5% CO 2 .
Measurements of intracellular calcium
Changes in intracellular calcium were measured by using a fluorescence microplate reader system with a built-in pipettor system (NOVOstar®, BMG LabTechnologies, Offenburg, Germany) according to the method described by Ullmann et al. [43] and by Kassack et al. [47] . The cells were seeded in 96-well plates at a density of 35,000 cells/well (1321N1 cells) or 45,000 cells/well (OVCAR-3 cells), respectively. After 24 h incubation at 37°C and 5% CO 2 , the medium was removed and the cells were washed with Krebs-HEPES buffer (KHB; 118.6 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 4.2 mM NaHCO 3 , 11.7 mM D-glucose, 10 mM HEPES (free acid), 1.3 mM CaCl 2 , and 1.2 mM MgSO 4 , pH 7.4) and loaded with 1.5 μM Oregon Green 488 BAPTA-1/AM (Molecular Probes) diluted in Krebs-HEPES buffer containing 0.03% Pluronic F-127 (Sigma-Aldrich, Taufkirchen, Germany) for 60 min (37°C/5% CO 2 ). After removing the Oregon Green, the cells were washed twice and 180 μl (agonist-mode)/160 μl (antagonist-mode) of Krebs-HEPES buffer were added. Concentration-response curves of agonists were generated by injection of 20 μl of increasing concentrations of ATP or UTP, respectively. Concentration-inhibition curves of antagonists were obtained by preincubation of cells with 20 μl of the test compound for 30 min at 37°C and subsequent injection of agonist (ATP or UTP, as indicated).
Combinatorial screening
Up to 16 different compounds were analyzed on one assay plate. Four different compounds were mixed and tested at two different concentrations (10 and 100 μM) by calcium assay. One millimolar suramin served as a control. 1321N1-P2Y 2 cells were preincubated with test compounds for 30 min at 37°C followed by the injection of agonist (ATP 50 nM, UTP 20 nM) using the NOVOstar®. If one combination was able to inhibit the agonist-induced calcium signal, the four compounds were then analyzed separately.
Electrophysiological evaluation at recombinant P2X receptors
The selectivity of NF198 and NF272 was evaluated at Xenopus laevis oocytes recombinantly expressing rat (r) or human (h) P2X receptors (rP2X 1 , hP2X 2 , and S16V-rP2X 3 ) using previously described protocols [43, 44] .
MTT cell viability assay
The MTT assay was used to determine the cytotoxicity of NF198 and NF272 as previously described [49, 50] . The cells were seeded in 96-well plates and incubated overnight at 37°C and 5% CO 2 . The seeding density depended on the growth characteristics of each cell line (1321N1, 3000 cells/ well; OVCAR-3, 9000 cells/well; HEK293, 4000 cells/well). After the overnight incubation, the culture medium was replaced by 90 μl of fresh medium and the cells were treated with 10 μl of increasing concentrations of each test compound. After 72 h incubation, 25 μl of MTT solution (5 mg/ml) was added to each well. The incubation with MTT was terminated after 5 min by removing the supernatant and adding 75 μl of DMSO to dissolve the formazan crystals. The absorption at 544 nm (test wavelength) and at 690 nm (reference wavelength) was measured using the FLUOstar® (BMG LabTechnologies, Offenburg, Germany).
Immunoblot analysis
Standard protocols were used for protein extraction and immunoblotting as described in [51] . Diluted protein samples were loaded onto a 10% SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride (PVDF) membrane by semi-dry blotting at 40 mA for 1 h. After blocking with 3% milk in TBST (10x TBST: 200 nM Tris, 9% NaCl, 1% Tween 20, pH 7.4) for 1 h, incubation with the specific primary antibody against P2Y 2 (dilution 1:200) was performed overnight at 4°C. After washing twice with TBST and once with TBS (10x TBS: 200 mM Tris, 9% NaCl, pH 7.4), incubation with the corresponding HRP-conjugated secondary antibody was performed for 1 h at room temperature. After washing the membrane again twice with TBST and once with TBS, the proteins were visualized using the Western Blotting Luminol Reagent (Santa Cruz Biotechnologies) and the INTAS Science Imaging Instrument (Gel iX Imager, Göttingen, Germany). β-Actin was used as a loading control.
Fluorescence imaging
According to published protocols [52] , the cells were grown on cover slides overnight. Then, the adherent cells were washed with PBS and fixed with 4% cold paraformaldehyde for 15 min. After washing with PBS, the non-specific binding sites were blocked with PBS 1x/3% bovine serum albumin for 1 h at room temperature, followed by incubation with primary antibody at 4°C overnight. After the removal of primary antibodies, the cells were washed three times with PBS and the fluorescence-labeled secondary antibody (Alexa Fluor 488 goat polyclonal to rabbit, A-11008) was added (1:500) for another 2 h at room temperature in the dark. After washing three times with PBS and staining of nuclear DNA by diamidino-2-phenylindole-dihydrochloride (DAPI) using the VECTASHIELD Antifade Mounting Medium (VECTOR LABORATORIES, LTD, Peterborough, UK), microscopic slides were analyzed by fluorescence microscopy using the Olympus BX43 (Olympus Europa Holding GmbH, Hamburg, Germany) or ArrayScan XTI Live High Content Platform (ThermoFisher Scientific Inc., USA).
Semi-quantitative real-time PCR
Total RNA was extracted from 0.5-1 × 10 6 cells using the myBudget RNA Mini Kit (Bio-Budget Technologies GmbH, Krefeld, Germany) according to the manufacturer's instructions. A total of 2 μg of purified mRNA was taken to prepare cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies GmbH, Darmstadt, Germany) and oligo(dT)23 anchored primers (Sigma-Aldrich, USA). The thermocycler program setting was initiated for 10 min at 25°C then followed by 120 min at 37°C. A total of 20 μl of cDNA was diluted in 100 μl TE buffer 1x (1 mM of Tris-Cl and 0.1 mM EDTA in distilled water) pH 7.5 and stored at − 20°C. The RT-PCR was performed by using 10 μl of the 2X QuantiTect-SYBR®Green-Master-Mix (Qiagen GmbH, Hilden, Germany), 1.5 μl of diluted cDNA, and 0.8 μl of forward and reverse primer (125 μM) filled up with water to a final volume of 20 μl, and was carried out with Mastercycler®personal (Eppendorf AG, Hamburg, Germany) programmed as follows: 95°C for 120 s as first step ensued by 40 cycles at 94°C for 20 s, 57°C for 30 s, and 72°C for 60 s. PCR products were separated by 2.0% agarose gel electrophoresis and after GelRed™ staining visualized by using the INTAS Gel iX Imager (INTAS Science Imaging, Goettingen, Germany). ß-Actin was used as a control (housekeeping gene). Forward and reverse primer pairs are listed in Table S2 .
Data analysis
To generate concentration-effect curves of agonists, effects of single doses of agonists (ATP or UTP) were expressed as the percentage of the maximum calcium fluorescence signal obtained in the experiment. Effects of combined or single doses of antagonists were expressed as percentage of agonist control response (50 nM ATP, 20 nM UTP, respectively). Apparent functional K i and pK i values were calculated according to the equation of Cheng and Prusoff [53] : 50 is the 50% inhibitory concentration of the antagonist, EC 50 is the 50% effective concentration of the agonist used in the experiment, and L is the molar concentration of the used agonist. EC 50 values for agonists and IC 50 values for antagonists were derived from −log concentration-effect (inhibition) curves by fitting pooled normalized data to the nonlinear fourparameter logistic equation (Prism 4.00; GraphPad Software, San Diego, USA). The SCHILD analysis was performed as previously described [54] [55] [56] . Additionally, analysis according to Lew and Angus was performed [57] . The MTT data were evaluated as follows: absorption at the reference wavelength was subtracted from the absorption at the test wavelength. Concentration-response curves were generated by nonlinear regression curve fitting using the four-parameter logistic equation as explained above. IC 50 is the concentration of the tested compound leading to a decrease of 50% of the control signal. All experiments were performed in triplicates and repeated at least three times.
Results
Screening of a suramin-derived library at recombinant P2Y 2 receptors P2Y 2 receptor-expressing 1321N1 cells (1321N1-P2Y 2 ) were stimulated by increasing the concentrations of ATP or UTP resulting in an increase in cytosolic Ca 2+ concentration monitored by fluorescence calcium assay [43] . The concentrationeffect curves are displayed in Fig. 2a . Kinetic records of the calcium assay (typical patterns of [Ca 2+ ] i responses to 1 μM ATP, 1 μM UTP, or KREBS-Hepes buffer as control) are shown in Figure S1A . As described in the literature, the human P2Y 2 receptor is activated by ATP and UTP with similar potency. In our test system, ATP has an EC 50 of 25 nM (pEC 50 = 7.64 ± 0.05) and UTP of 10 nM (pEC 50 = 7.99 ± 0.07). These findings are in a similar range as published data [9] . The expression of P2Y 2 receptors in transfected 1321N1 cells was confirmed by western blot analysis and immunofluorescence microscopy (Fig. 2b) . As expected, the wildtype 1321N1 cells did not express P2Y 2 receptor proteins either in western blot or in immunofluorescence experiments. On the other hand, these experiments demonstrated the successful expression of P2Y 2 receptor proteins in 1321N1-P2Y 2 cells after transfection. Notably, the P2Y 2 receptor seemed to be expressed by forming dimers or heteromers because of the five different bands detected in the western blot experiment. This fact is in line with recently published data by von Kügelgen et al. [12] and Abe et al. [58] describing the formation of dimers by P2Y 2 receptors or the formation of heteromers with P1A 1 [59] or with P2Y 1 receptors [60] .
A total of 415 suramin-derived compounds were screened for antagonist effects at P2Y 2 receptors as described in the "Materials and methods" section "Combinatorial screening." Three compounds, NF198, NF272, and NF292 (chemical structure, see Fig. 1 ), inhibited the response induced by 50 nM ATP (Fig. 2c) . One micromolar suramin served as an inhibition control. Interestingly, only NF272 was able to fully inhibit the signal induced by 20 nM UTP. NF292 and NF198 were not able to inhibit the UTP-induced response in 1321N1-P2Y 2 cells to the same extent as the ATP-induced response.
The concentration-effect curves of NF198, NF272, NF292, and suramin for inhibition of 50 nM ATP signal are displayed in Fig. 2d . IC 50 , pIC 50 , and apparent functional K i values are summarized in Table 1 . Thus, NF198 is 12-fold, NF272 14-fold, and NF292 is 8-fold more potent than suramin in our calcium studies. The concentration-inhibition curves of NF198, NF272, and NF292 show Hill coefficients not significantly different from unity. Since NF292 was approximately 2-fold less potent than NF198 and NF272, further experiments were undertaken only with NF198 and NF272.
Cytotoxicity of NF198 and NF272
To determine the antiproliferative properties of the most potent P2Y 2 antagonists NF198 and NF272, we tested both compounds in the MTT cell viability assay using the non-cancer cell line HEK293, the astrocytoma cell line 1321N1, and the ovarian cancer cell line OVCAR-3. Concentration-response curves are displayed in Fig. 3a , IC 50 values summarized in Table 2 (pIC 50 values ± SEM are listed in supplemental information Table S1 ). NF198 demonstrated significantly higher cytotoxicity than NF272. In all cell lines, NF198 is nearly 10-fold more cytotoxic than NF272 (Table 2 ). Figure 3b confirms a lack of cytotoxic effects of NF272 in all three cell lines up to a concentration of 250 μM, whereas 250 μM NF198 kills more than 50% of the cells. A total of 10 μM cisplatin was used as a positive control. Due to the unfavored cytotoxic Effects of NF272 in the native P2Y 2 expression system OVCAR-3
Next, we studied the effect of NF272 in a cellular system with physiologically expressed P2Y 2 receptors. The human ovarian cancer cell line OVCAR-3 is reported to natively express P2Y 2 receptors [61] [62] [63] . First, the expression of P2Y 2 receptors was confirmed by semi-quantitative PCR analysis, western blotting, and immunofluorescence microscopy ( Fig. 3c) . The PCR experiments indicated that OVCAR-3 cells are expressing P2Y 6 besides P2Y 2 receptors. In western blot experiments, P2Y 2 receptors are shown to form dimers in this ovarian cancer cell line. Next, the concentration-effect curves of ATP and UTP were monitored using the fluorescence calcium assay. Kinetic records of the calcium assay (typical patterns of [Ca 2+ ] i responses to 1 μM ATP, 1 μM UTP, or KREBSHepes buffer) in OVCAR-3 cells are shown in Figure S1B . ATP gave an EC 50 of 86 nM, and UTP gave an EC 50 of 30 nM in OVCAR-3 cells (Fig. 3d) , indicating an effect via P2Y 2 and not P2Y 6 . EC 50 values were in the same range as data obtained in the recombinant cell line 1321N1-P2Y 2 . Then, the inhibitory effect of NF272 on ATP-induced calcium release was studied. Indeed, NF272 inhibited the response of 200 nM ATP (approx. 2× EC 50 ) in OVCAR-3 cells with similar potency as was found in recombinant 1321N1-P2Y 2 ( Fig. 3e) : IC 50 = 58 μM (recombinant 1321N1-P2Y 2 ); IC 50 = 21 μM (OVCAR 3). Suramin gave comparable results. IC 50 , pIC 50 , and K i values are listed in Table 1 (1321N1-P2Y 2 ) and Table 3 (OVCAR-3). NF272 is thus a useful antagonist in recombinantly as well as natively P2Y 2 receptor-expressing cells. To examine the mode of inhibition by NF272 of P2Y 2 receptors, concentration-response curves of ATP were monitored in the absence and presence of increasing concentrations of NF272 at recombinant 1321N1-P2Y 2 . Figure 5a shows the rightward shift of ATP concentration-response curves. EC 50 values are summarized in Table 6 . Analyses according to SCHILD [54] [55] [56] and Lew and Angus were performed [57] . (Fig. 5c ). pK D (Lew and Angus) was estimated as 4.96 ± 0.11 (mean ± SEM) and slope was not significantly different from unity.
Discussion
P2Y 2 receptors are widely expressed all over the human body and involved in many (patho)physiological functions [2, 7, 8, 11] . The number of P2Y 2 receptor ligands is still manageable (Fig. 1a) , and only one potent and selective P2Y 2 antagonist is available, namely AR-C118925 with a nanomolar IC 50 value of 57 nM [41] . Suramin has long been known to inhibit various P2X and P2Y receptors [7, 9] . However, suramin is neither potent nor selective for any P2 receptor subtype [1, 64] , and suramin shows a broad range of side effects and a complex toxicological profile at concentrations inhibiting the P2Y 2 receptor limiting the use of suramin in in vitro and in vivo experiments [65] . In the past, our group has contributed a variety of purinergic ligands derived from suramin [42] [43] [44] [45] [46] . In this study, we aimed to screen for potent and selective P2Y 2 receptor ligands in a library containing approximately 415 suramin-derived compounds (Fig. 1b) . Surprisingly, only three compounds (NF198, NF272, NF292) turned out as medium micromolar antagonists (Fig. 2c, d , Table 1 ). These suramin-derived compounds did by far not reach the potency of AR-C118925 (IC 50 57 nM). However, the potency of NF198, NF272, and NF292 is up to 14-fold higher than suramin (Table 1) . NF292 is a terephthalic acid bisamide and showed the highest IC 50 among these three compounds (96 μM). NF198 is a symmetrical suramin-type urea and equipotent to NF272 which contains only one-half of the suramin structure and a phenyl-carbamate moiety instead of urea. Notably, the amino or nitro precursors of suramin differing from NF272 only by lack of the phenyl-carbamate residue were totally inactive at P2Y 2 receptors up to a concentration of 100 μM (data not shown). These results confirm that a central urea bridge and a symmetrical structure are not mandatory for interaction with the P2Y 2 receptor. Half of the suramin molecule as NF272 with only one cluster of anionic charges is sufficient for P2Y 2 antagonism and achieves the same potency as the large suramin-type urea NF198 differing from suramin by replacement of two methyl by phenyl groups. The structure-activity relationships are summarized in Fig. 6 . Furthermore, although NF198 and NF272 are equipotent at P2Y 2 receptors (63 and 58 μM, respectively, Table 1 ), NF272 is approximately 10-fold less cytotoxic at cancer and noncancer cell lines, increasing the suitability of NF272 in cellular studies (Fig. 3a, b, Table 2 ). NF272 is a competitive antagonist (Fig. 5) . The pA 2 (5.03, SCHILD analysis) or pK D values (4.96, Lew and Angus analysis) of NF272 are in accordance with its pK i from inhibition curves (4.72, Fig. 2d, Table 1 ). A drawback of NF272 is the lack of selectivity for P2Y 2 over purinergic receptors. Whereas most suramin-derived purinergic antagonists are potent and selective [42] [43] [44] [45] [46] , NF272 preferentially inhibits ATP/ADP-preferring P2Y 11 , rP2X 1 , and P2Y 12 (Table 4) . Only among uracil-nucleotide activated P2Y receptors, NF272 has a mild preference for P2Y 2 over P2Y 4 (3.6-fold) and P2Y 6 (5.7-fold) (Fig. 4 , Table 4 ). In addition, NF272 inhibited ATP-induced calcium release in human ovarian cancer cells OVCAR-3 expressing natively P2Y 2 and P2Y 6 receptors ( Fig. 3c) with similar potency as was found in recombinant 1321N1-P2Y 2 (Fig. 3e) .
In conclusion, this study shows that suramin-derived ligands can serve as P2Y 2 antagonists with > 10-fold increased potency compared with suramin. Downsizing suramin to half (containing only one anionic cluster) yielded the competitive antagonist NF272 with 14-fold higher potency at P2Y 2 than suramin, moderate preference for P2Y 2 over P2Y 4 and P2Y 6 , but no selectivity over other purinergic receptors, and no cytotoxic effects up to 250 μM. NF272 can thus serve as a hit for the development of suramin-derived P2Y 2 antagonists.
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